Company intelligence / Profile preview
Telix Pharmaceuticals Limited
North Melbourne, Victoria, Australiatelixpharma.com ↗
- Ownership
- Public · TLX
- Employees
- ~234
- Development stage
- Other
01
Overview
Telix has received global regulatory approvals from the Australian TGA, U.S. FDA, and Health Canada for its prostate cancer imaging agent Illuccix®. The company has 18 clinical trials underway worldwide across various disease areas[1][4].
- Therapeutic areas
- OncologyRare DiseasesHematology
- Modalities
- RadiopharmaceuticalsTheranosticsTargeted radiation therapy
- Industry
- Biotech
02
Drug pipeline
47 assets46 more assets in the full pipeline.
03
Financials
- Market cap
- $3.2B
- Total revenue
- $789.8M
- Enterprise value
- $3.5B
Beyond the preview
Go deeper on Telix Pharmaceuticals Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telix Pharmaceuticals Limited.